





PHARMACEUTICAL 2023

Petros Pharmaceuticals Inc.
Rank 263 of 446



The relative strengths and weaknesses of Petros Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Petros Pharmaceuticals Inc. compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 79% points. The greatest weakness of Petros Pharmaceuticals Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 62% points.

The company's Economic Capital Ratio, given in the ranking table, is 36%, being 7.0% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	14,668
Cost of Goods Sold	2,289
Intangible Assets	12,244
Liabilities, Current	7,068
Liabilities, Non-Current	263
Other Assets	5,470
Other Compr. Net Income	0
Other Expenses	10,265
Other Liabilities	8,388
Other Net Income	474
Other Revenues	5,992
Property and Equipment	39
Research and Development	1,740
Selling, General and Administrative Expense	12,209

Output Variable	Value in 1000 USD
Assets	32,421
Liabilities	15,719
Expenses	26,504
Revenues	5,992
Stockholders Equity	16,702
Net Income	-20,038
Comprehensive Net Income	-20,038
Economic Capital Ratio	36%